TG4070, an individualized neoantigen vaccine, enters Phase 1 trial for resected NSCLC, leveraging proprietary AI-driven selection and scalable manufacturing. The myvacⓇ platform expands its reach, with TG4050 progressing in head and neck cancer and further technological advancements supporting broader deployment.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.